![]() |
市場調查報告書
商品編碼
2008823
內視鏡再處理市場報告:按產品、製程、最終用戶和地區分類(2026-2034 年)Endoscope Reprocessing Market Report by Product, Process, End User, and Region 2026-2034 |
||||||
2025年,全球內視鏡器械再處理市場規模達24.7億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到42.3億美元,2026年至2034年的複合年成長率(CAGR)為5.97%。推動該市場成長的主要因素是微創手術需求的不斷成長以及感染控制日益嚴格的法規。此外,再處理設備的快速技術進步、患者安全意識的提高以及內視鏡檢查數量的激增也促進了市場成長。
對微創手術的需求日益成長
微創手術日益普及是內視鏡器械再處理市場成長的主要驅動力。這些利用內視鏡進行的手術相比傳統手術具有許多優勢,例如恢復時間更短、感染風險更低、術後疼痛更輕。根據美國國家生物技術資訊中心(NCBI)發布的數據,美國每年約進行1770萬例胃腸內視鏡檢查,佔所有內視鏡檢查的68%。胃腸內視鏡檢查後的整體感染率為0.2%,但某些手術的感染率較高。具體而言,ERCP(逆行性造影)的感染率為0.8%,除ERCP以外的上消化道內視鏡檢查的感染率為0.123%,下消化道內視鏡檢查的感染率為0.073%。因此,內視鏡檢查的頻率不斷增加,對有效再處理解決方案的需求也隨之增加,以確保內視鏡的安全性和耐用性。
提出嚴格的感染管制條例
產業報告顯示,軟式內視鏡消毒不徹底與醫院感染(HAI)密切相關,對病患和醫療系統帶來沉重負擔。醫院感染是患者最常通報的不利事件,在歐洲的發生率高達6.5%。手術部位感染佔所有醫院感染的18.3%,會對病患的生活品質產生負面影響,增加發病率和死亡率。此外,手術部位感染也會對醫療系統帶來巨大的經濟負擔。在德國,手術部位感染平均可使住院時間延長17.9天,並使每位患者額外支出22,905歐元。因此,世界各國政府和醫療機構正在實施嚴格的法規來預防醫院感染。為了遵守這些法規並避免處罰,醫療機構正在投資先進的內視鏡消毒系統。這確保了內視鏡得到徹底的清潔、消毒和滅菌,從而降低醫院感染的風險並提高病患安全。
再處理設備的技術進步
技術進步正顯著推動內視鏡再處理市場的成長。自動化再處理系統、高性能消毒劑和先進的追蹤系統等創新技術提高了再處理流程的效率和可靠性。這些技術是內視鏡再處理解決方案普及和推廣的關鍵因素,因為它們確保內視鏡始終保持高標準的清潔度,降低人為錯誤的風險,並簡化醫療工作流程。例如,2023年1月,領先的軟性機器人器械開發商Agilis Robotics完成了其第二次使用自主研發的內視鏡手術機器人進行的動物活體試驗。結果顯示,該機器人系統在有效性、準確性和安全性方面均取得了令人鼓舞的成果。因此,預計機器人技術在內鏡手術中的日益普及將導致手術數量的增加,從而推動市場成長。
The global endoscope reprocessing market size reached USD 2.47 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.23 Billion by 2034, exhibiting a growth rate (CAGR) of 5.97% during 2026-2034. The market is primarily being driven by the rising demand for minimally invasive surgeries, and the implementation of stringent regulations on infection control. Additionally, rapid technological advancements in reprocessing equipment, growing awareness about patient safety, and the surging prevalence of endoscopy procedures are further contributing to the market growth.
Increasing Demand for Minimally Invasive Surgeries
The rising preference for minimally invasive surgeries is acting as a major driver for the endoscope reprocessing market growth. These procedures, which use endoscopes, offer benefits such as reduced recovery time, lower risk of infection, and less postoperative pain compared to traditional surgeries. According to the data published on National Center for Biotechnology, approximately 17.7 million gastrointestinal (GI) endoscopic procedures are performed annually in the United States, accounting for 68% of all endoscopic procedures. The composite infection rate following GI endoscopic procedures was 0.2%, with higher rates for specific procedures: 0.8% for ERCP, 0.123% for non-ERCP upper GI endoscopies, and 0.073% for lower GI endoscopies. As a result, the frequency of endoscopic procedures is increasing, leading to a higher demand for effective reprocessing solutions to ensure the safety and longevity of endoscopes.
Implementation of Stringent Infection Control Regulations
As per industry reports, failures in reprocessing flexible endoscopes are associated with hospital-acquired infections (HAIs), which place a significant burden on patients and healthcare systems. HAIs are the most reported adverse events affecting patients, with a prevalence of 6.5% across Europe. Surgical site infections, comprising 18.3% of all HAIs, negatively affect patient quality of life and increase morbidity and mortality rates. They also contribute to a significant financial burden on healthcare systems. In Germany, surgical site infections can lead to an average hospital stay extension of 17.9 days and an additional healthcare cost of €22,905 per patient. As a result, governments and healthcare organizations worldwide are implementing stringent regulations to prevent hospital-acquired infections (HAIs). To comply with these regulations and avoid penalties, healthcare facilities are investing in advanced endoscope reprocessing systems. This ensures that endoscopes are thoroughly cleaned, disinfected, and sterilized, thereby reducing the risk of HAIs and improving patient safety.
Technological Advancements in Reprocessing Equipment
Advancements in technologies are significantly driving the endoscope reprocessing market growth. Innovations, such as automated reprocessing machines, enhanced disinfectants, and sophisticated tracking systems, have improved the efficiency and reliability of the reprocessing process. These technologies ensure that endoscopes are consistently cleaned to high standards, reduce the risk of human error, and streamline the workflow in healthcare facilities, making them a critical factor in the adoption and expansion of endoscope reprocessing solutions. For instance, in January 2023, Agilis Robotics, a leading developer of flexible robotic instruments, completed its second round of live animal testing with its proprietary robot for endoscopic surgery. The results demonstrated promising outcomes in terms of efficacy, accuracy, and safety of the robotic system. Consequently, the increasing integration of robotics in endoscopic surgery is expected to boost the number of procedures performed, thereby driving market growth.
High-level disinfectants and test strips account for the majority of the market share
High-level disinfectants and test strips are enhancing the endoscope reprocessing market value due to their effectiveness and efficiency in ensuring patient safety. These disinfectants are specifically designed to eliminate a broad spectrum of pathogens, including highly resistant organisms such as Mycobacterium tuberculosis and Clostridium difficile. Their fast-acting nature and compatibility with automated reprocessors make them a preferred choice in busy healthcare settings. Test strips play a crucial role in validating the efficacy of the disinfection process, providing immediate confirmation that the minimum recommended concentration of the disinfectant is met, thus ensuring compliance with safety standards and reducing the risk of infections. For instance, RAPICIDE high-level disinfectant is a glutaraldehyde-based, fast-acting, reusable solution for flexible endoscopes in automated reprocessors, requiring no mixing or activation. It reprocesses heat-sensitive, semi-critical medical devices in systems like the DSD-201, inactivating pathogens such as TB, C-diff, and CRE with a 5-minute contact time at 95°F (35°C). The disinfectant enhances efficiency with only two rinses needed. RAPICIDE(TM) Test Strips confirm the minimum recommended concentration of glutaraldehyde, requiring a 3-second dip and a 75-second read time. This example illustrates how specific products drive the demand for high-level disinfectants and test strips in the market, thereby increasing the endoscope reprocessing market value.
Automated cleaning holds the largest share of the industry
Automated cleaning dominates the endoscope reprocessing market due to its ability to ensure consistent and high-level disinfection, reducing the risk of human error associated with manual cleaning. Automated systems, such as automated endoscope reprocessors (AERs), provide standardized, efficient, and effective cleaning and disinfecting processes, which are critical for patient safety. These systems enhance workflow efficiency within healthcare facilities by minimizing both the time and labor involved in reprocessing endoscopes. Additionally, automated cleaning systems are specifically designed to accommodate the intricate designs of modern endoscopes, ensuring thorough decontamination and adherence to stringent regulatory standards. As part of the endoscope reprocessing market forecast, it is expected that the growing adoption of automated cleaning solutions will continue to shape the market, driven by advancements in technology and the increasing demand for reliable and efficient reprocessing methods.
For instance, in March 2023, PENTAX Medical, a division of the HOYA Group, was awarded the CE mark for its innovative automated pre-cleaning solution, the AquaTYPHOON. Developed in collaboration with PlasmaBiotics, this device offers a robust alternative to the traditional manual pre-cleaning step in endoscope reprocessing, effectively addressing the hygiene challenges healthcare providers encounter in daily clinical practice.
Hospitals and clinics represent the leading market segment
The endoscope reprocessing market research report highlights that hospitals and clinics are the dominant segment in the market, attributed to the large volume of endoscopic procedures conducted within these facilities. According to industry reports, the number of bariatric surgery procedures in Ireland reached 219 in 2023, significantly surpassing the revised target of 200 set by the Health Service Executive (HSE). This marked a substantial increase from the 109 procedures performed in 2022. These surgeries were conducted at three HSE sites: St Vincent's University Hospital in Dublin, St Michael's Hospital in Dun Laoghaire, and University Hospital Galway. Additionally, University Hospital Galway alone performed 49 surgeries in 2023, up from 19 in the previous year.
These facilities require stringent infection control measures to prevent hospital-acquired infections, making effective reprocessing essential. The increasing prevalence of minimally invasive surgeries, which frequently utilize endoscopes, further drives demand. Additionally, regulatory requirements and guidelines mandate rigorous reprocessing protocols to ensure patient safety. The combination of high procedural volume, regulatory compliance, and the critical need for infection prevention establishes hospitals and clinics as the primary market segment for endoscope reprocessing.
North America leads the market, accounting for the largest endoscope reprocessing market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for endoscope reprocessing.
North America's dominance in the endoscope reprocessing market can be attributed to its advanced healthcare infrastructure, increasing prevalence of chronic diseases, stringent regulatory standards, and high frequency of endoscopic procedures. For example, a 2024 article by the American Society of Anesthesiologists indicates that approximately 6.1 million upper endoscopies are performed annually in the U.S. Furthermore, the CDC reports that around 129 million Americans suffer from at least one major chronic condition, significantly driving the need for endoscope reprocessing solutions. As endoscopic procedures become more common for both diagnostic and therapeutic purposes, the endoscope reprocessing market outlook reflects a growing demand for effective reprocessing technologies. The region's healthcare systems, equipped with sophisticated technologies and protocols, ensure effective endoscope reprocessing to prevent infections. Additionally, heightened awareness of infection control among healthcare providers and patients, along with continuous technological advancements and a focus on patient safety, further solidify North America's leading position in the market.